Bangalore, Mar 18, 2010: Sun Pharmaceutical announced that the USFDA has granted its subsidiary an approval for its ANDA for Promethazine Hydrochloride and Codeine Phosphate Oral Syrup, 6.25 mg/5 ml and 10mg/5ml.

This Promethazine Hydrochloride with Codeine Phosphate Oral Syrup is bioequivalent to Prometh w/Codeine of Actavis Mid Atlantic. This product has annual sales of approximately $16 mn in the US.

This medication is used to treat symptoms caused by the common cold, flu, allergies, or other breathing illnesses such as sinusitis and bronchitis.